Antares Pharma Stock Price and Value Analysis

Should you buy Antares Pharma stock? (NasdaqCM:ATRS). Let's see how it does in our automated value investing analysis system.

  • This company is less known than others.
  • This company is not making money.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ATRS Numbers

ATRS Price
(Antares Pharma stock price per share)
[?] PE Ratio versus Sector 26% lower than other Healthcare stocks
[?] PE Ratio versus Industry 37% lower than other Medical Instruments & Supplies stocks
[?] Cash Yield -0.20%
[?] Free Cash Flow Jitter 57%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 7,275,885 shares shorted. With 155,611,584 shares available for purchase and an average trading volume over the past 10 trading days of 2,371,335, it would take at least 3.068 days for all of the short holders to cover their shorts.

Is Antares Pharma Stock on Sale?

Based on our analysis, we believe that you should not buy Antares Pharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ATRS Stock?

Does Antares Pharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.